BioSpace News Archive

Immunocore Holdings plc today announced that it will report full year 2023 results, before the US markets open on Wednesday, February 28, 2024.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies.

Emergent BioSolutions Inc. today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024.

Verge Genomics announced today that Verge Co-founder and CEO Alice Zhang will present at the virtual Evercore ISI 2024 Emerging Biotech Conference, on Wednesday, February 28th from 10:45 a.m. – 11:15 a.m. EST.

Zimmer Biomet Holdings, Inc. today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2024.

Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya , Chief Executive Officer of Nanoscope Therapeutics, and other members of its senior management team will participate in two upcoming conferences.

Lutris Pharma today announced the publication of data from its phase 1/2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for the treatment of radiation-induced dermatitis (RD) in patients with breast cancer.

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that the Company will report fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2023 financial results.

Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial.